Contineum Therapeutics (CTNM)

• Market cap: $309M
• 1 day: -1.61%
• 5 days: 0.36%
• 1 month: -6.68%
• 3 months: 100.18%
• 6 months: 145.11%
• Year to date: -23.83%
• 1 year: -35.38%
• 5 years: -28.38%
• 10 years: -28.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Employees: 41